This material is educational and describes substances as research-use reagents. It is not medical advice and not a usage instruction for humans.
If Ozempic made the GLP-1 class popular, Mounjaro went further, it's already a dual agonist. Behind the brand is the molecule tirzepatide, working on two receptors at once. Let's unpack what that means, how tirzepatide differs from semaglutide, and how, when buying research-use tirzepatide, not to end up with a fake.
What Mounjaro and tirzepatide are
Mounjaro is a brand name whose active substance is tirzepatide. Unlike semaglutide (a GLP-1-only agonist), tirzepatide is a dual GIP and GLP-1 agonist: it activates two incretin receptors at once.
GLP-1 and GIP are two incretin hormones released after eating. Semaglutide works with one, tirzepatide with both. This "dual" mechanism is exactly what sets Mounjaro apart from Ozempic at the molecular level.
The dual mechanism: GLP-1 + GIP
- The GLP-1 component, satiety, slower gastric emptying, glucose-dependent insulin release (the same as semaglutide).
- The GIP component, an additional incretin pathway also involved in glucose and lipid metabolism.
Mounjaro vs Ozempic: the difference
| Ozempic | Mounjaro | |
|---|---|---|
| Active substance | semaglutide | tirzepatide |
| Mechanism | GLP-1 | GLP-1 + GIP |
| Form | injection | injection |
| Injection frequency | once weekly | once weekly |
| Weight change in trials | up to 14.9% at 68 weeks (STEP 1) | up to 20.9% at 72 weeks (SURMOUNT-1) |
In short: Ozempic is semaglutide, one receptor; Mounjaro is tirzepatide, two receptors. We covered semaglutide in detail in a separate article on Ozempic. There is a third case nearby: the Saxenda brand, built on liraglutide, a daily GLP-1 agonist.
Efficacy from the trial data
Both molecules were studied in large randomized trials in people with overweight or obesity. In STEP 1 (Wilding et al., NEJM, 2021), semaglutide at 2.4 mg weekly produced an average weight loss of about 14.9% from baseline at 68 weeks. In SURMOUNT-1 (Jastreboff et al., NEJM, 2022), tirzepatide at the highest 15 mg dose produced an average weight loss of about 20.9% at 72 weeks. Both trials used a gradual dose escalation over several months, not a fixed dose from week one.
These figures describe an approved drug under medical supervision inside a clinical trial, not an outcome to expect from a research-use reagent outside a controlled protocol.
Side effects: a shared profile
In both trials, the most commonly reported side effects were gastrointestinal: nausea, diarrhea, constipation and vomiting. They are mostly mild to moderate, occur more often during dose escalation, and tend to ease over time. Because of its added GIP component, tirzepatide showed a somewhat different frequency of individual symptoms compared with semaglutide in some studies, but the overall profile stays similar since both drugs work by stimulating the GLP-1 receptor.
This is a description of the profile from approved clinical trials, not dosing or usage instructions for a research-use reagent in humans.
Zepbound and analogues
- Zepbound, the same tirzepatide under a different brand (like Wegovy for semaglutide).
- Research-use tirzepatide, the same molecule as a research reagent, without the brand markup, but also without pharmacy guarantees. And here, as always, it all comes down to one thing: how is it proven that this really is tirzepatide and that it's pure?
Research-use tirzepatide: how to verify purity (COA)
- COA (Certificate of Analysis) for a specific batch confirms identity (it really is tirzepatide) and the purity percentage by an independent lab assay.
- Batch verification, at longeva every batch ships with a COA, and a lot can be opened at
/verify/{lot}. - Red flags: no COA; one certificate "for everything"; a seller only in a messenger; a suspiciously low price "for the same purity." More detail in our piece on research-use and COA.
The rule is the same as for semaglutide: verifiable purity over price.
Price and availability in Ukraine
Branded Mounjaro means a prescription, a high price and periodic shortages. Research-use tirzepatide is more affordable but shifts responsibility for quality onto the buyer, which is why a COA and batch verification become a requirement, not a bonus.
Frequently asked questions
Is tirzepatide "stronger" than semaglutide?
By the average figures from the trials above, tirzepatide in SURMOUNT-1 produced a larger average weight loss than semaglutide in STEP 1. But these are different trials, different populations and different follow-up periods, so a plain "stronger/weaker" comparison oversimplifies it. Both mechanisms are well described in the literature, and the actual choice is a question for a physician, not a blog article.
Can research-use tirzepatide and semaglutide be compared by eye?
No. A research reagent does not go through the same controls as an approved drug, and only that specific batch's COA confirms its quality, not the brand or the molecule name on the label.
How does Zepbound differ from Mounjaro?
It's the same tirzepatide under different brands and indications (like Wegovy and Ozempic for semaglutide), not a different molecule.
A seller says "verified", is that enough without a COA?
No, a seller's word does not replace the document. See the COA and red-flags section above.
See on Longeva
Research-use Semaglutide with an open COA. Full overview in the wiki.
